Judith Buentzel1, Judith Heinz2, Annalen Bleckmann3, Christoph Bauer4, Christian Röver2, Hanibal Bohnenberger5, Shekhar Saha6, Marc Hinterthaner6, Hassina Baraki6, Ingo Kutschka6, Alexander Emmert7. 1. Department of Haematology and Medical Oncology, Georg-August University, Göttingen, Germany. 2. Department of Medical Statistics, Georg-August University, Göttingen, Germany. 3. Comprehensive Cancer Center Münster, University Medical Center, University Münster, Münster, Germany. 4. Department of Nephrology and Hypertension, Center for Internal Medicine and Medical Clinic III, Klinikum Fulda, Fulda, Germany. 5. Institute of Pathology, University Medical Centre, Göttingen, Germany. 6. Department of Thoracic and Cardiovascular Surgery University Medical Center, Georg-August University, Göttingen, Germany. 7. Department of Thoracic and Cardiovascular Surgery University Medical Center, Georg-August University, Göttingen, Germany alexander.emmert@med.uni-goettingen.de.
Abstract
BACKGROUND/AIM: Sarcopenia describes the loss of skeletal muscle mass. While this condition is associated with a high mortality in cancer patients, its influence on survival is still underestimated. PATIENTS AND METHODS: A systematic review for articles was performed using the PubMed database, Cochrane Library, Biomed Central, Science Direct and by manual search. We used data of overall survival in sarcopenic patients for assessing the death risk. We extracted hazard ratio estimates from univariate and multivariate Cox proportional hazards models for meta-analysis. RESULTS: A total of 15 studies were eligible for meta-analysis including a total of 2,521 lung cancer patients. Univariate meta-analysis revealed a two-fold increased death risk in sarcopenic patients; multivariate meta-analysis yielded a significant, three-fold elevated risk of death. This higher mortality is independent of tumour stage. CONCLUSION: Muscle loss is an independent risk factor for increased death risk in lung cancer patients independent of cancer stage. This argues for implementing screening for sarcopenia into cancer care. Copyright
BACKGROUND/AIM: Sarcopenia describes the loss of skeletal muscle mass. While this condition is associated with a high mortality in cancerpatients, its influence on survival is still underestimated. PATIENTS AND METHODS: A systematic review for articles was performed using the PubMed database, Cochrane Library, Biomed Central, Science Direct and by manual search. We used data of overall survival in sarcopenic patients for assessing the death risk. We extracted hazard ratio estimates from univariate and multivariate Cox proportional hazards models for meta-analysis. RESULTS: A total of 15 studies were eligible for meta-analysis including a total of 2,521 lung cancerpatients. Univariate meta-analysis revealed a two-fold increased death risk in sarcopenic patients; multivariate meta-analysis yielded a significant, three-fold elevated risk of death. This higher mortality is independent of tumour stage. CONCLUSION: Muscle loss is an independent risk factor for increased death risk in lung cancerpatients independent of cancer stage. This argues for implementing screening for sarcopenia into cancer care. Copyright
Authors: Corine de Jong; Najiba Chargi; Gerarda J M Herder; Simone W A van Haarlem; Femke van der Meer; Anne S R van Lindert; Alexandra Ten Heuvel; Jan Brouwer; Pim A de Jong; Lot A Devriese; Alwin D R Huitema; Toine C G Egberts; Remco de Bree; Vera H M Deneer Journal: J Cachexia Sarcopenia Muscle Date: 2022-03-18 Impact factor: 12.063
Authors: Chris Burtin; Jacques Bezuidenhout; Karin J C Sanders; Anne-Marie C Dingemans; Annemie M W J Schols; Stephanie T H Peeters; Martijn A Spruit; Dirk K M De Ruysscher Journal: J Cachexia Sarcopenia Muscle Date: 2020-02-11 Impact factor: 12.910